Health Care [ 3/12 ] | Pharmaceuticals [ 18/75 ]
NASDAQ | Common Stock
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles.
It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz.
Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 26 | 0.15 Increased by +133.33% | 0.19 Decreased by -21.96% |
| Nov 3, 25 | -0.04 Increased by +89.69% | -0.41 Increased by +90.24% |
| Aug 12, 25 | -0.49 Decreased by -32.43% | -0.42 Decreased by -16.67% |
| May 12, 25 | -0.45 Increased by +16.67% | -0.42 Decreased by -7.14% |
| Mar 11, 25 | -0.45 Decreased by -7.14% | -0.40 Decreased by -13.92% |
| Nov 5, 24 | -0.39 Decreased by -61.58% | -0.37 Decreased by -4.81% |
| Aug 7, 24 | -0.37 Decreased by -2.78% | -0.34 Decreased by -8.82% |
| May 13, 24 | -0.54 Decreased by -200.00% | -0.32 Decreased by -68.75% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 92.02 M Increased by +3.05 K% | 14.55 M Increased by +137.93% | Increased by +15.82% Increased by +101.20% |
| Sep 30, 25 | 54.34 M Increased by +1.12 K% | -3.53 M Increased by +84.74% | Decreased by -6.50% Increased by +98.75% |
| Jun 30, 25 | 8.84 M Increased by +141.51% | -41.58 M Decreased by -48.80% | Decreased by -470.51% Increased by +38.39% |
| Mar 31, 25 | 3.12 M Increased by +4.98% | -38.37 M Increased by +6.26% | Decreased by -1.23 K% Increased by +10.70% |
| Dec 31, 24 | 2.92 M Decreased by -35.62% | -38.37 M Decreased by -39.78% | Decreased by -1.32 K% Decreased by -117.12% |
| Sep 30, 24 | 4.45 M Increased by +20.94% | -23.16 M Decreased by -46.64% | Decreased by -520.57% Decreased by -21.26% |
| Jun 30, 24 | 3.66 M Decreased by -23.55% | -27.94 M Decreased by -18.82% | Decreased by -763.65% Decreased by -55.41% |
| Mar 31, 24 | 2.97 M Decreased by -33.85% | -40.93 M Decreased by -248.47% | Decreased by -1.38 K% Decreased by -426.81% |